The Middleby Corporation
MIDDThe Middleby Corporation's three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it.
The sharpest disagreement: the price moved −2.1% in a year while annual EPS moved −166.7% — the difference is re-rating, and re-rating has to be repaid with earnings.
The price is building a base (5 weeks in) while the P/E sits at the 56th percentile of its own 4-year range. Underneath, the last four quarters read mixed — profit +0.0% year on year, and 162% of the last 3 years' profit arrived as cash. What settles it: whether earnings grow into a price that has already moved.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
The Middleby Corporation trades at $139, building a base and 5 weeks into that stage. That is −3.8% against its own 200-day average. It sits at 37% of a 52-week range of $118 to $175. On relative strength it is currently behind the S&P 500 on a trailing-13-week view (5 weeks and counting).
Today the stock is building a base — week 5 of stage 1. At $139 it trades −3.8% versus its 200-day average and sits at 37% of its 52-week range ($118–$175).
Against the market, two honest reads. Cumulative: over the last 10.1 years the stock moved +20% while the S&P 500 moved +263% — behind the index over the full window. Recent form: on a trailing-13-week view the stock is currently behind (5 weeks and counting; last ahead the week of 2026-07-02) — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Valuation P/E is the price of $1 of annual profit: how many dollars the market pays for each dollar the company earns in a year.
The Middleby Corporation trades at 18.2× P/E, mid-range by its own standards (56th percentile). Its long-run median P/E is 17.9×, measured across 3.8 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 18.2× is mid-range by its own standards (56th percentile), against a long-run median of 17.9× measured over 3.8 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
🚨 Why the multiple sits where it does: over the past year annual EPS moved −166.7% against a −2.1% price move — the price outran earnings, pushing the multiple UP its own range.
The price move, decomposed: over 3y, of the −0.9%/yr price move, ~−0.3%/yr came from earnings growth and ~−0.6 pp from the multiple (roughly flat). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.
Put together: the multiple is unremarkable against its own past, so the story rests on the earnings line underneath it, not the multiple.
Stage: Deteriorating Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
The Middleby Corporation reads as deteriorating on its fundamental arc. Deteriorating — revenue, profit and EPS growth are shrinking (revenue growth −14.7% latest against +10.3% at its 12-quarter best), ROCE holding at 9.8%. The read is built from 12 quarters across 4 curves, on full evidence.
🚨 Why it matters: falling curves mean every cheap-looking ratio below needs a discount for direction.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +1.6% | −0.4% | — | — |
| Profit | −11.9% | −3.4% | — | — |
| Stock price | −2.1% | −0.9% | −6.4% | +1.3% |
4-Factor Sector Score
39.3/100 — rank 26 of 30 in Specialty Industrial Machinery · 56% evidence confidence
The Middleby Corporation scores 39.3 out of 100 against the 30 companies it is compared with in Specialty Industrial Machinery, ranking 26. Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
The four contributions add to the total exactly: 16.3 + 9.3 + 11.4 + 2.3 = 39.3. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
The Middleby Corporation reported $0.8 B of revenue in the Apr 26 quarter, +15.1% year on year. Over 4 years it has compounded at −0.4% a year. The last full year, FY26, came in at $3.2 B. The last four reported quarters add to $3.1 B.
FY26 revenue came in at $3.2 B (+1.6% on the year), capping 4 years at −0.4% compound. The latest quarter (Apr 26) printed $0.8 B, +15.1% year on year.
Pace check: the last four quarters averaged −12.2% growth against the decade's −0.4% — the current year is running slower than its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew −14.7% over the last 4 quarters against −11.1%/yr over the last 8 — rolling over.
Operating margin Operating margin is what is left of every $100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
The Middleby Corporation's operating margin is 15.5% in the Apr 26 quarter, −2.3 percentage points against the same quarter a year ago. Across 5 fiscal years the operating margin has ranged 15.9% to 20.3%. The current quarter is running below every full year in that window.
The latest quarter's operating margin is 15.5%, −2.3 pp against the same quarter a year ago. Across 5 fiscal years the operating margin has ranged 15.9%–20.3%.
🚨 Why the margin moved: operating margin went −2.3 pp year on year while gross margin went −1.6 pp — the loss came mostly from the gross line: input costs and pricing.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
The Middleby Corporation earned $0.1 B of net profit in the Apr 26 quarter, +0.0% year on year. Full-year FY26 profit was $0.4 B. The 4-year compound rate is −6.8%. That is 10.7% of the quarter's revenue. The same quarter a year earlier earned $0.1 B. 1 of the last 12 reported quarters were loss-making.
Apr 26 profit was $0.1 B, +0.0% year on year. On the full year, FY26 printed $0.4 B (−11.9%), and the 4-year compound rate is −6.8%.
🚨 Why profit moved: revenue contributed +15.1% and the margin −2.3 pp — the quarter was revenue-led despite a thinner margin.
Pace comparison, last four quarters: profit −158.9% vs revenue −12.2%. Profit is growing slower than sales — costs are eating the growth before it reaches the bottom line.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 162% of The Middleby Corporation's reported profit arrived as operating cash — the cash follows the profit. In FY26 that was $0.6 B of operating cash against $0.4 B of profit. After $0.1 B of capital spending, $0.6 B was left as free cash.
FY26: operating cash of $0.6 B against reported profit of $0.4 B, leaving free cash of $0.6 B after $0.1 B of capital spending. Across the last 3 fiscal years the conversion rate is 162% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
Why: conversion is measured cleanly, but the working-capital day-counts behind it sit below what we hold — the move is shown without inventing its driver.
Router verdict: the visible cash user is investment — the next section checks what the spending is buying.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
The Middleby Corporation does not report the debtor, inventory and payable day-counts a cash cycle is built from, so this section reads the investment side instead. Capital spending ran $0.0 B over the last 3 years. Averaged over those years that is 0.0% of FY26 revenue a year.
Working-capital day-counts are not in our numbers for this stock, so this section reads the investment side — where the cash is being put to work.
On the investment side: capital spending of $0.0 B over the last 3 fiscal years.
The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.
Return on equity Return on equity (ROE) is the profit the business earns on its shareholders’ money. With the full capital-employed split not in our numbers, ROE is the cleanest long ladder we can draw here.
The Middleby Corporation earns a ROE of 13% in FY26. That is up from a trough of 12% in FY25. Return on invested capital clears the cost of that capital by +0.3 percentage points, so growth here adds value rather than only size. The wiring behind it is 11.6% net margin on 0.51× asset turns.
FY26 ROE is 13%, recovered from a FY25 trough of 12% — the full ladder below shows the fall and the climb, undoctored.
Why the return is what it is — the wiring (FY26): 11.6% net margin × 0.51× asset turns × 2.27× balance-sheet leverage ≈ 13.4% on equity. Margin does its share; leverage is a meaningful part of the equation.
The capstone test — ROIC − WACC: 10.2% − 9.9% = a +0.3 pp spread. The 9.9% is an estimate of this company's own cost of capital — read the sign and the size of the spread, not the decimals. Positive but thin — value creation with little room for error.
Dividend
The Middleby Corporation pays no dividend. Across the last 12 reported quarters it has declared no dividend per share, so there is no payout history to chart and no yield to quote. Companies at this stage typically reinvest earnings rather than distribute them, which makes the cash-flow and reinvestment sections the place that cash shows up.
The Middleby Corporation does not currently pay a dividend. Across the last 12 reported quarters the company has declared no dividend per share, so there is no payout history to chart and no yield to quote. Companies at this stage typically reinvest earnings instead of distributing them.
Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.
The Middleby Corporation carries total debt of $1.9 B against shareholder equity of $2.4 B as of Apr 26, a debt-to-equity of 0.79. On the annual view that ratio went from 0.97 in FY22 to 0.78 in FY26. Read the returns elsewhere on this page with that leverage in mind.
Apr 26: total debt of $1.9 B against shareholder equity of $2.4 B — a debt-to-equity of 0.79. On the annual view, debt-to-equity went from 0.97 (FY22) to 0.78 (FY26). Read the returns on this page with that leverage in mind.
Ownership There is no quarter-by-quarter holder register to read here, so we read the crowd through short interest — the slice of tradable shares currently sold short, positioned for a fall.
4.6% of The Middleby Corporation's tradable float is currently sold short — some money is positioned against it. At typical trading volumes those positions would take about 2.1 days to buy back. There is no quarter-by-quarter holder register to read for this filer, so the crowd is read through short interest instead.
The latest reading: 4.6% of the float is sold short, and at typical trading volumes it would take about 2.1 days to buy those positions back. Some money is positioned against it. This is a single point-in-time reading — we do not yet hold its history, so we show no trend chart.
Why it sits there: who is doing the shorting, and why, does not travel with the number — the level is shown without inventing its story.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
The Middleby Corporation: the Z-score reads 3.61. A Z-score above roughly 3 reads as safe and below roughly 1.8 as the distress zone, so this sits well clear of distress. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure.
Why it matters: a Z-score of 3.61 sits well clear of the distress zone — the balance sheet is not the risk here.
The safety line in one sentence: the Z-score reads 3.61.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1Watts Water Technologies, Inc.WTS | 73.4/100Favorable setup81% evidence | BREAKING OUT | 27.1/35 Revenue 14.3% · PAT 25.3% · OPM change 3.9 pp 83% evidence | 15.1/25 ROCE 5.9% · OPM 19.6% 76% evidence | 13.3/20 P/E 26.3× · PEG 1.04 65% evidence | 17.9/20 RS sector 7.5% · RS bench 7.1% · 1Y 36.6%7 of 12 weeks ahead 100% evidence |
| Exact sum: 27.1 + 15.1 + 13.3 + 17.9 = 73.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 2Donaldson Company, Inc.DCI | 66.5/100Favorable setup85% evidence | TURNING | 25.4/35 Revenue 4.4% · PAT 20.9% · OPM change 6.3 pp 95% evidence | 15.2/25 ROCE 6.7% · OPM 15.6% 76% evidence | 14.6/20 P/E 23.7× · PEG 0.95 65% evidence | 11.3/20 RS sector -0.1% · RS bench -0.5% · 1Y 36.1%2 of 12 weeks ahead 100% evidence |
| Exact sum: 25.4 + 15.2 + 14.6 + 11.3 = 66.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 3Illinois Tool Works Inc.ITW | 61.6/100Thin evidence · provisional58% evidence | TURNING | 20.1/35 Revenue — · PAT — · OPM change 0.6 pp 45% evidence | 17.4/25 ROCE 10.1% · OPM 25.4% 76% evidence | 10.8/20 P/E 24.5× · PEG — 15% evidence | 13.3/20 RS sector 1% · RS bench 0.7% · 1Y 14.8%2 of 12 weeks ahead 100% evidence |
| Exact sum: 20.1 + 17.4 + 10.8 + 13.3 = 61.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 4Nordson CorporationNDSN | 60.4/100Mixed-positive evidence85% evidence | TURNING | 20.9/35 Revenue 7.4% · PAT 18.4% · OPM change 1.9 pp 95% evidence | 13.9/25 ROCE 3.6% · OPM 26.6% 76% evidence | 11.0/20 P/E 30.8× · PEG 1.5 65% evidence | 14.6/20 RS sector 6.7% · RS bench 6.3% · 1Y 46.7%0 of 12 weeks ahead 100% evidence |
| Exact sum: 20.9 + 13.9 + 11 + 14.6 = 60.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 5IDEX CorporationIEX | 58.1/100Thin evidence · provisional58% evidence | TURNING | 18.7/35 Revenue — · PAT — · OPM change 2 pp 45% evidence | 12.2/25 ROCE 3.1% · OPM 19.4% 76% evidence | 9.8/20 P/E 32.7× · PEG — 15% evidence | 17.4/20 RS sector 11.5% · RS bench 11.2% · 1Y 50.3%4 of 12 weeks ahead 100% evidence |
| Exact sum: 18.7 + 12.2 + 9.8 + 17.4 = 58.1 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 6Emerson Electric Co.EMR | 56.8/100Mixed-positive evidence81% evidence | TURNING | 20.3/35 Revenue 4% · PAT 27.1% · OPM change -0.3 pp 83% evidence | 13.3/25 ROCE 3.5% · OPM 24.2% 76% evidence | 8.2/20 P/E 30.3× · PEG 2.1 65% evidence | 15.0/20 RS sector 3.2% · RS bench 2.9% · 1Y 19.7%2 of 12 weeks ahead 100% evidence |
| Exact sum: 20.3 + 13.3 + 8.2 + 15 = 56.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 7Rockwell Automation, Inc.ROK | 55.6/100Mixed-positive evidence81% evidence | FADING | 23.4/35 Revenue 10.5% · PAT 8.4% · OPM change 3.9 pp 83% evidence | 15.6/25 ROCE 6.3% · OPM 20.9% 76% evidence | 9.1/20 P/E 37.3× · PEG 1.76 65% evidence | 7.5/20 RS sector 0.2% · RS bench 0.1% · 1Y 33.6%10 of 12 weeks ahead 100% evidence |
| Exact sum: 23.4 + 15.6 + 9.1 + 7.5 = 55.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 8AMETEK, Inc.AME | 52.9/100Mixed-positive evidence81% evidence | TURNING | 18.1/35 Revenue 9.5% · PAT 7.8% · OPM change 0.4 pp 83% evidence | 14.5/25 ROCE 3.9% · OPM 26.7% 76% evidence | 4.9/20 P/E 32.4× · PEG 3.88 65% evidence | 15.4/20 RS sector 7.1% · RS bench 6.7% · 1Y 39.5%0 of 12 weeks ahead 100% evidence |
| Exact sum: 18.1 + 14.5 + 4.9 + 15.4 = 52.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 9Crane CompanyCR | 52.8/100Thin evidence · provisional58% evidence | BREAKING OUT | 14.5/35 Revenue — · PAT — · OPM change -3.7 pp 45% evidence | 12.0/25 ROCE 5.2% · OPM 14.4% 76% evidence | 9.1/20 P/E 39× · PEG — 15% evidence | 17.2/20 RS sector 5.4% · RS bench 5.2% · 1Y 15.5%9 of 12 weeks ahead 100% evidence |
| Exact sum: 14.5 + 12 + 9.1 + 17.2 = 52.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 10Eaton Corporation plcETN | 52.8/100Thin evidence · provisional58% evidence | TURNING | 14.2/35 Revenue — · PAT — · OPM change -3.1 pp 45% evidence | 12.8/25 ROCE 3.7% · OPM 15.7% 76% evidence | 8.9/20 P/E 43.3× · PEG — 15% evidence | 16.9/20 RS sector 7.4% · RS bench 7.3% · 1Y 22.6%1 of 12 weeks ahead 100% evidence |
| Exact sum: 14.2 + 12.8 + 8.9 + 16.9 = 52.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 11Gates Industrial Corporation plcGTES | 52.7/100Thin evidence · provisional56% evidence | TURNING | 15.6/35 Revenue — · PAT — · OPM change -1.9 pp 39% evidence | 7.8/25 ROCE 2% · OPM 12.9% 76% evidence | 11.1/20 P/E 19.2× · PEG — 15% evidence | 18.2/20 RS sector 8.4% · RS bench 8.2% · 1Y 26.3%6 of 12 weeks ahead 100% evidence |
| Exact sum: 15.6 + 7.8 + 11.1 + 18.2 = 52.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 12Graco Inc.GGG | 51.7/100Thin evidence · provisional58% evidence | TURNING | 17.4/35 Revenue — · PAT — · OPM change -1.8 pp 45% evidence | 16.4/25 ROCE 6.6% · OPM 25.5% 76% evidence | 10.9/20 P/E 24× · PEG — 15% evidence | 7.0/20 RS sector -10.8% · RS bench -11.1% · 1Y -1.4%0 of 12 weeks ahead 100% evidence |
| Exact sum: 17.4 + 16.4 + 10.9 + 7 = 51.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 13Otis Worldwide CorporationOTIS | 51.7/100Thin evidence · provisional58% evidence | BASING | 17.1/35 Revenue — · PAT — · OPM change 2.8 pp 45% evidence | 18.6/25 ROCE 18.6% · OPM 15.1% 76% evidence | 11.3/20 P/E 18.4× · PEG — 15% evidence | 4.7/20 RS sector -20.8% · RS bench -20.9% · 1Y -15.8%0 of 12 weeks ahead 100% evidence |
| Exact sum: 17.1 + 18.6 + 11.3 + 4.7 = 51.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 14Ingersoll Rand Inc.IR | 49.9/100Thin evidence · provisional58% evidence | TURNING | 18.7/35 Revenue — · PAT — · OPM change -1.9 pp 45% evidence | 10.4/25 ROCE 2.4% · OPM 15.7% 76% evidence | 9.5/20 P/E 33.7× · PEG — 15% evidence | 11.3/20 RS sector -1.2% · RS bench -1.6% · 1Y 17.9%1 of 12 weeks ahead 100% evidence |
| Exact sum: 18.7 + 10.4 + 9.5 + 11.3 = 49.9 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 15GE Vernova Inc.GEV | 48.9/100Thin evidence · provisional58% evidence | ASLEEP | 19.0/35 Revenue — · PAT — · OPM change 1.4 pp 45% evidence | 6.0/25 ROCE 2.9% · OPM 1.9% 76% evidence | 9.7/20 P/E 32.8× · PEG — 15% evidence | 14.2/20 RS sector 15.7% · RS bench 15.1% · 1Y 56.9%5 of 12 weeks ahead 100% evidence |
| Exact sum: 19 + 6 + 9.7 + 14.2 = 48.9 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 16Parker-Hannifin CorporationPH | 48.6/100Mixed-negative evidence81% evidence | TURNING | 14.5/35 Revenue 6% · PAT 2.6% · OPM change -0.4 pp 83% evidence | 14.7/25 ROCE 4.8% · OPM 20.7% 76% evidence | 6.7/20 P/E 33× · PEG 2.38 65% evidence | 12.7/20 RS sector 1.6% · RS bench 1.1% · 1Y 36.4%2 of 12 weeks ahead 100% evidence |
| Exact sum: 14.5 + 14.7 + 6.7 + 12.7 = 48.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 17Generac Holdings Inc.GNRC | 47.6/100Thin evidence · provisional58% evidence | ASLEEP | 22.2/35 Revenue — · PAT — · OPM change 2.2 pp 45% evidence | 11.3/25 ROCE 4.8% · OPM 11.1% 76% evidence | 8.7/20 P/E 67.5× · PEG — 15% evidence | 5.4/20 RS sector -1.2% · RS bench -1.5% · 1Y 11.4%7 of 12 weeks ahead 100% evidence |
| Exact sum: 22.2 + 11.3 + 8.7 + 5.4 = 47.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 18Flowserve CorporationFLS | 47.0/100Thin evidence · provisional58% evidence | TURNING | 15.1/35 Revenue — · PAT — · OPM change -0.3 pp 45% evidence | 8.9/25 ROCE 3.3% · OPM 11.2% 76% evidence | 10.6/20 P/E 26× · PEG — 15% evidence | 12.4/20 RS sector 2.2% · RS bench 1.5% · 1Y 52.6%1 of 12 weeks ahead 100% evidence |
| Exact sum: 15.1 + 8.9 + 10.6 + 12.4 = 47 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 19Enpro Inc.NPO | 46.2/100Mixed-negative evidence81% evidence | FADING | 12.4/35 Revenue 10.2% · PAT -50% · OPM change -0.9 pp 83% evidence | 6.6/25 ROCE 1.8% · OPM 14.4% 76% evidence | 12.3/20 P/E 123.5× · PEG 0.95 65% evidence | 14.9/20 RS sector 15.5% · RS bench 15.1% · 1Y 56.5%10 of 12 weeks ahead 100% evidence |
| Exact sum: 12.4 + 6.6 + 12.3 + 14.9 = 46.2 · Decision use: Price leads the evidence: RS versus the benchmark is 15.1%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 20Xylem Inc.XYL | 45.3/100Thin evidence · provisional58% evidence | TURNING | 19.4/35 Revenue — · PAT — · OPM change 0.3 pp 45% evidence | 9.7/25 ROCE 2.6% · OPM 11.5% 76% evidence | 10.2/20 P/E 28.1× · PEG — 15% evidence | 6.0/20 RS sector -16.4% · RS bench -16.4% · 1Y -14.4%0 of 12 weeks ahead 100% evidence |
| Exact sum: 19.4 + 9.7 + 10.2 + 6 = 45.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 21A. O. Smith CorporationAOS | 44.6/100Thin evidence · provisional58% evidence | TURNING | 12.5/35 Revenue — · PAT — · OPM change -1.9 pp 45% evidence | 14.2/25 ROCE 6.5% · OPM 17.1% 76% evidence | 11.5/20 P/E 17.4× · PEG — 15% evidence | 6.4/20 RS sector -15.1% · RS bench -15.3% · 1Y -10.5%0 of 12 weeks ahead 100% evidence |
| Exact sum: 12.5 + 14.2 + 11.5 + 6.4 = 44.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 22Cummins Inc.CMI | 44.4/100Mixed-negative evidence81% evidence | ASLEEP | 7.4/35 Revenue 0.1% · PAT -3.6% · OPM change -2.6 pp 83% evidence | 11.1/25 ROCE 4.2% · OPM 11.3% 76% evidence | 15.1/20 P/E 27.9× · PEG 0.8 65% evidence | 10.8/20 RS sector 4.9% · RS bench 4.4% · 1Y 64.3%5 of 12 weeks ahead 100% evidence |
| Exact sum: 7.4 + 11.1 + 15.1 + 10.8 = 44.4 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 23Regal Rexnord CorporationRRX | 42.8/100Mixed-negative evidence81% evidence | ASLEEP | 15.0/35 Revenue 1.5% · PAT 22% · OPM change -1 pp 83% evidence | 5.8/25 ROCE 1.2% · OPM 10.3% 76% evidence | 7.7/20 P/E 43.5× · PEG 1.94 65% evidence | 14.3/20 RS sector 12.6% · RS bench 12% · 1Y 58.3%2 of 12 weeks ahead 100% evidence |
| Exact sum: 15 + 5.8 + 7.7 + 14.3 = 42.8 · Decision use: Price leads the evidence: RS versus the benchmark is 12%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 24Dover CorporationDOV | 41.8/100Thin evidence · provisional58% evidence | ASLEEP | 16.3/35 Revenue — · PAT — · OPM change -1 pp 45% evidence | 11.8/25 ROCE 3.5% · OPM 14.9% 76% evidence | 10.4/20 P/E 27× · PEG — 15% evidence | 3.3/20 RS sector -5.6% · RS bench -6% · 1Y 21%0 of 12 weeks ahead 100% evidence |
| Exact sum: 16.3 + 11.8 + 10.4 + 3.3 = 41.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 25Pentair plcPNR | 41.6/100Thin evidence · provisional58% evidence | BASING | 16.2/35 Revenue — · PAT — · OPM change 0.2 pp 45% evidence | 12.2/25 ROCE 3% · OPM 20.3% 76% evidence | 11.2/20 P/E 18.9× · PEG — 15% evidence | 2.0/20 RS sector -34.9% · RS bench -34.9% · 1Y -33.3%0 of 12 weeks ahead 100% evidence |
| Exact sum: 16.2 + 12.2 + 11.2 + 2 = 41.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 26The Middleby Corporationthis pageMIDD | 39.3/100Thin evidence · provisional56% evidence | ASLEEP | 16.3/35 Revenue — · PAT — · OPM change 0 pp 39% evidence | 9.3/25 ROCE 2.4% · OPM 15.9% 76% evidence | 11.4/20 P/E 17.5× · PEG — 15% evidence | 2.3/20 RS sector -12.6% · RS bench -12.9% · 1Y 15.9%3 of 12 weeks ahead 100% evidence |
| Exact sum: 16.3 + 9.3 + 11.4 + 2.3 = 39.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 27Symbotic Inc.SYM | 39.2/100Mixed-negative evidence61% evidence | BASING | 25.2/35 Revenue 21.4% · PAT — · OPM change 4.6 pp 62% evidence | 3.0/25 ROCE 0.6% · OPM 0.9% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 1.0/20 RS sector -22.7% · RS bench -22.7% · 1Y -14.7%0 of 12 weeks ahead 100% evidence |
| Exact sum: 25.2 + 3 + 10 + 1 = 39.2 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -22.7% and the one-year return is -14.7%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth. | ||||||
| 28JBT Marel CorporationJBTM | 37.9/100Mixed-negative evidence74% evidence | ASLEEP | 25.1/35 Revenue 78.2% · PAT — · OPM change 11.2 pp 62% evidence | 5.5/25 ROCE 1% · OPM 7.3% 76% evidence | 4.4/20 P/E 40× · PEG 3.63 65% evidence | 2.9/20 RS sector -14.9% · RS bench -15.1% · 1Y -2.4%1 of 12 weeks ahead 100% evidence |
| Exact sum: 25.1 + 5.5 + 4.4 + 2.9 = 37.9 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -14.9% and the one-year return is -2.4%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth. | ||||||
| 29ITT Inc.ITT | 35.9/100Thin evidence · provisional58% evidence | ASLEEP | 11.8/35 Revenue — · PAT — · OPM change -6.3 pp 45% evidence | 9.0/25 ROCE 2.3% · OPM 11.7% 76% evidence | 9.4/20 P/E 34.1× · PEG — 15% evidence | 5.7/20 RS sector -2.1% · RS bench -2.4% · 1Y 23.5%0 of 12 weeks ahead 100% evidence |
| Exact sum: 11.8 + 9 + 9.4 + 5.7 = 35.9 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 30Chart Industries, Inc.GTLS | 24.4/100Adverse evidence71% evidence | 5.0/35 Revenue -1.5% · PAT -121.4% · OPM change -9.3 pp 83% evidence | 4.7/25 ROCE 0.7% · OPM 5.9% 76% evidence | 8.5/20 P/E 687.4× · PEG — 15% evidence | 6.2/20 RS sector -3.5% · RS bench -5.2% · 1Y 22.2%0 of 9 weeks ahead 100% evidence | |
| Exact sum: 5 + 4.7 + 8.5 + 6.2 = 24.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led S&P 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is The Middleby Corporation's stock price today?
The Middleby Corporation trades at $139, −2.1% over the past year. The company is valued at $6.0 B. The stock sits at 37% of its 52-week range of $118–$175, −3.8% versus its 200-day average. On the tape, the price is building a base, 5 weeks in. — as of 5 August 2026.
What were The Middleby Corporation's latest quarterly results?
The Middleby Corporation reported revenue of $0.8 B and net profit of $0.1 B for the Apr 26 quarter. Revenue rose 15.1% and profit rose 0.0% year on year. The operating margin was 15.5%, 2.3 pp lower than a year earlier. — as of 5 August 2026.
What is The Middleby Corporation's revenue?
The Middleby Corporation reported revenue of $0.8 B in the Apr 26 quarter, +15.1% year on year. For the full FY26 fiscal year, revenue was $3.2 B (+1.6%). Over the last 4 years revenue compounded at −0.4% a year. — as of 5 August 2026.
What is The Middleby Corporation's profit?
The Middleby Corporation earned $0.1 B of net profit in the Apr 26 quarter, +0.0% year on year. Full-year FY26 profit was $0.4 B. The operating margin ran 15.5% in the latest quarter. — as of 5 August 2026.
What is The Middleby Corporation's market cap?
The Middleby Corporation's market capitalisation is $6.0 B at a stock price of $139. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 5 August 2026.
What is The Middleby Corporation's P/E ratio?
The Middleby Corporation trades at a P/E of 18.2×, at the 56th percentile of its own 4-year range, against a long-run median of 17.9×. This is a comparison with the stock's own history, not a value call — as of 5 August 2026.
Does The Middleby Corporation pay a dividend?
No — The Middleby Corporation has declared no dividend per share in any of its last 12 reported quarters, so there is no payout history and no yield to quote. That is a reading of the filed statements, not an estimate. — as of 5 August 2026.
Is The Middleby Corporation overvalued?
On its own history, The Middleby Corporation looks mid-range against its own history: its P/E of 18.2× sits at the 56th percentile of its 4-year range (long-run median 17.9×). That is a percentile read against the stock's own past, not a price opinion or a direction call. — as of 5 August 2026.
Is The Middleby Corporation growing?
The picture is mixed for The Middleby Corporation: latest-quarter revenue +15.1% year on year, profit +0.0%, and the margin −2.3 pp at 15.5%. The 4-year compound rates are −0.4% (revenue) and −6.8% (profit). The earnings engine currently reads: mixed — as of 5 August 2026.
How is The Middleby Corporation performing?
The Middleby Corporation is building a base, 5 weeks in. Its latest quarter's revenue rose 15.1% and profit rose 0.0% year on year. Against the S&P 500 it has been behind on a trailing-13-week view for 5 weeks. This describes what the data did, not a rating. — as of 5 August 2026.
What stage is The Middleby Corporation in?
Deteriorating — revenue, profit and EPS growth are shrinking (revenue growth −14.7% latest against +10.3% at its 12-quarter best), ROCE holding at 9.8%. The read comes from the last 12 quarters of growth (revenue growth −14.7% latest, profit growth −162.8% latest, eps growth −205.7% latest) plus the ROCE curve, classified by deterministic rules — a trajectory read, not a buy or sell call — as of 5 August 2026.
Is The Middleby Corporation in an uptrend?
No — the price is building a base (week 5 of stage 1), trading −3.8% versus its 200-day average and at 37% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 5 August 2026.
Is The Middleby Corporation beating the market?
Not lately — on a trailing-13-week view The Middleby Corporation is currently behind the S&P 500 (5 weeks and counting; last ahead the week of 2026-07-02), the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 10.1 years the stock moved +20% against the S&P 500's +263% — behind the index over the full window. — as of 5 August 2026.
Will The Middleby Corporation's stock price go up?
This page publishes no price forecast for The Middleby Corporation. What it measures instead: the stock price is $139, the price is building a base 5 weeks in. Its P/E of 18.2× sits at the 56th percentile of its own 4-year range. — as of 5 August 2026.
Is the market betting against The Middleby Corporation?
Somewhat — short interest is 4.6% of The Middleby Corporation's tradable float, about 2.1 days to cover at typical volumes. A moderate reading: some money is positioned against it. With no quarter-by-quarter holder register here, short interest is the cleanest crowd read we hold — as of 5 August 2026.
Does The Middleby Corporation have too much debt?
It is moderate — The Middleby Corporation's debt-to-equity is 0.80. A year-by-year borrowings ladder is not in our numbers for this stock, so the latest reading is the cleanest hold. Read the returns on this page with that leverage in mind — as of 5 August 2026.
What is The Middleby Corporation's capex?
The Middleby Corporation spent $0.0 B on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY26 alone that was $0.1 B. — as of 5 August 2026.
What is The Middleby Corporation's cash flow?
The Middleby Corporation generated $0.6 B of operating cash flow in FY26 and $0.6 B of free cash flow after $0.1 B of capital spending. Reported profit that year was $0.4 B, so operating cash ran ahead of profit. — as of 5 August 2026.
Is The Middleby Corporation's profit real cash?
Yes — over the last 3 fiscal years, 162% of The Middleby Corporation's reported profit arrived as operating cash. In FY26, operating cash was $0.6 B against reported profit of $0.4 B. The cash then goes mostly into building capacity. Cash-flow resolution is annual — as of 5 August 2026.
How financially safe is The Middleby Corporation?
On the balance sheet, the Z-score reads 3.61 — above roughly 3 is safe, below roughly 1.8 is the distress zone. That sits well clear of trouble. — as of 5 August 2026.
Where is The Middleby Corporation in its business cycle?
The Middleby Corporation's FY26 operating margin was 17.8%, against a 5-year band of 15.9%–20.3%: mid-band by its own history — neither the peak that precedes mean-reversion nor the trough that precedes recovery. The latest quarter ran 15.5%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 5 August 2026.
What could break the The Middleby Corporation story?
The sharpest disagreement: the price moved −2.1% in a year while annual EPS moved −166.7% — the difference is re-rating, and re-rating has to be repaid with earnings. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 5 August 2026.
Is The Middleby Corporation a stock worth studying right now?
This is not investment advice. The machine read: The Middleby Corporation's three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it. The sharpest open question: whether earnings grow into a price that has already moved. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 5 August 2026.